跳至主要内容
临床试验/ACTRN12618001449224
ACTRN12618001449224尚未招募未知

The effect of a beta-3 adrenergic receptor agonist on metabolic disease in humans.

Baker Heart and Diabetes Institute0 个研究点目标入组 60 人开始时间: 2018年8月28日最近更新:

试验速览

阶段
未知
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
20 Years 至 50 Years(—)
性别
All

入选标准

  • Age 20-50 years
  • BMI: 30-40 kg/m2
  • HOMA-IR: greater than or equal to 2.0

排除标准

  • Alcohol consumption >3 (male) or >2 (female) standard drinks per day
  • Blood ALT concentration >3 times upper limit of normal (ULN) (ULN: female <20 IU/l, male <30 IU/l)
  • Hepatitis or autoimmune liver disease
  • History of type 1 or 2 diabetes
  • History of obstructive urinary symptoms
  • History of established cardiovascular disease (prior hospitalisation or medication for any cardiovascular disease or risk factor)
  • Currently taking any prescription medications that alter cardiometabolic parameters, prior use of anti-hypertensive medications and medications primarily acting via ß-ARs. Oral contraceptives are acceptable if treatment has been established for greater than 6 months.
  • Established renal disease or eGFR <60 ml/min/1.73m2
  • Pregnant or breastfeeding women
  • History of cancer other than non-melanoma skin cancer
  • History of major psychiatric illness, psychosis or major depressive disorder

研究者

相似试验